With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

CLICK HERE FOR CME CREDIT

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting? 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Michael Davidson, MD, FACC, FACP, FNLA

Michael Davidson, MD, FACC, FACP, FNLA

Clinical Professor Director of Preventive Cardiology The University of Chicago Hospitals and Clinic Pritzker School of Medicine Chicago, Illinois